CSI Market
Sign In | Register

Myriad Genetics Inc (MYGN) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access MYGN quarterly Cash Flow →
Quarterly cash flow trends provide additional context on Myriad Genetics Inc's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-365.90
Depreciation & amortization53.70
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Asset Impairment Charges319.40
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-3.20
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation35.20
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), before Tax, Total0.00
Non Cash Interest Expense-
Costmethod Investments Other Than Temporary Impairment-
Increase Decrease In Unrecognized Tax Benefits-32.50
Unrecognized Tax Benefits Period Increase Decrease-
Change In Fair Value Of Contingent Consideration-
Impairment Of Goodwill And Long Lived Assets Held For Use-
Goodwill And Intangible Asset Impairment-
Operating Lease Right Of Use Asset Amortization Expense7.70
Gain Loss On Termination Of Lease-
Asset Acquisition Gain Loss-
Income taxes0.10
Marketable Securities, Realized Gain (Loss), Excluding Other than Temporary Impairments, Total0.00
Increase (Decrease) in Accounts Receivable6.20
Increase (Decrease) in Accounts Payable-1.40
Increase (Decrease) in Accrued Liabilities-27.50
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets4.60
Other Working Capital2.00
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities3.40
Discontinued operations0.00
Net Cash flow from Operating Activities1.80
Investing Activities
Capital Expenditures-27.40
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale, Maturity and Collection of Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Proceeds from Divestiture of Interest in Consolidated Subsidiaries0.00
Proceeds from Divestiture of Businesses, Net of Cash Divested0.00
Accounts payable0.00
Receivables0.00
Payments to Acquire Projects0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-27.40
Financing Activities
Short-term debt Net-40.50
Other borrowing transactions-8.60
Long-term debt - borrowings125.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock3.30
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-7.50
Proceeds From Repayments Of Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options-
Change In Cash And Cash Equivalents Classified As Held For Sale-
Finance Lease Principal Payments-
Payments For Release Of Escrow-7.50
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities64.20
Effect of exchange rate on cash flow0.80
Discontinued operations0.00
Free Cash Flow-25.60
Total Cash Flow39.40
4 historic quarters locked

Sign in to unlock the full Myriad Genetics Inc cash flow history.

Sign In Create Free Account

About Myriad Genetics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 24, 2026
  • Source: mygn-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000899923-26-000018

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License